Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRAS G12C inhibitor resistant tumors

The clinical success of KRAS inhibitors (G12Ci) including AMG510 and MRTX849 is limited by the eventual development of acquired resistance. A novel and effective treatment to revert or target this resistance is urgent. To this end, we established G12Ci (AMG510 and MRTX849) resistant KRAS mutant canc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Redox biology 2024-12, Vol.78, p.103419
Hauptverfasser:	Wang, Kai, Zhang, Xin, Fan, Yufei, Zhou, Liang, Duan, Yajun, Li, Su, Sun, Zhongkan, Zhang, Chunqian, Yang, Haoyu, Yuan, Wenxiu, Peng, Linyuan, Ma, Xiaoyu, Xiang, Siliang, Wang, Tianzhi, Yang, Mei, Zhang, Zhenyuan, Wang, Jiaxuan, Wang, Zhongyuan, Qian, Minxian
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Transport System y+ - genetics Amino Acid Transport System y+ - metabolism Animals Antineoplastic Agents - pharmacology Cell Line, Tumor Drug Resistance, Neoplasm - genetics Ferroptosis - drug effects Ferroptosis - genetics Humans MAP Kinase Signaling System - drug effects Mice Neoplasms - drug therapy Neoplasms - genetics Neoplasms - metabolism Neoplasms - pathology Proto-Oncogene Proteins p21(ras) - genetics Proto-Oncogene Proteins p21(ras) - metabolism SOXB1 Transcription Factors - genetics SOXB1 Transcription Factors - metabolism Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!